An Analysis of Amyloid, Tau, and Inflammation in Alzheimer’s Disease
DOI:
https://doi.org/10.58445/rars.3999Keywords:
Alzheimer’s Disease, Amyloid-beta plaques, NeuroinflammationAbstract
Alzheimer’s disease (AD) is a progressive brain disorder that leads to memory loss, cognitive decline, and difficulty performing daily activities. Although current treatments mainly focus on managing symptoms, understanding the underlying causes of the disease can lead to more effective therapies and earlier detection. This report examines the roles of amyloid-beta plaques, tau protein tangles, and neuroinflammation in the development and progression of Alzheimer’s disease. Amyloid-beta plaques build up between neurons and disrupt communication, while tau tangles form inside neurons and block essential transport systems, leading to cell death. In addition, chronic neuroinflammation caused by overactive immune cells further damages brain tissue. By studying how these three factors interact, researchers can develop targeted treatments, such as antibody therapies, small-molecule drugs, and stem cell approaches, that aim to slow or stop disease progression. This research also supports the development of biomarkers, including protein levels in blood or cerebrospinal fluid and brain imaging techniques, which can detect Alzheimer’s disease at an early stage before major symptoms appear. This report also covers how lifestyle modifications, such as diet, regular exercise, and proper sleep, can help lower the risk of AD or slow its progression (Kivipelto et al., 2018). Overall, a better understanding of the biological processes of AD and factors which can ameliorate AD progression offers hope for earlier diagnosis, improved treatments, and potentially preventing Alzheimer’s disease in the future.
References
Benilova, I., Karran, E., & De Strooper, B. (2012). The toxic Aβ oligomer and Alzheimer’s disease: An emperor in need of clothes. Nature Neuroscience, 15(3), 349–357. https://doi.org/10.1038/nn.3028
Braak, H., & Braak, E. (1991). Neuropathological staging of Alzheimer-related changes. Acta Neuropathologica, 82(4), 239–259. https://doi.org/10.1007/BF00308809
Brier, M. R., Gordon, B., Friedrichsen, K., McCarthy, J., Stern, A., Christensen, J., … & Ances, B. M. (2016). Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease. Science Translational Medicine, 8(338), 338ra66. https://doi.org/10.1126/scitranslmed.aaf2362
Chen, Y., & Yu, Y. (2023). Tau and neuroinflammation in Alzheimer’s disease: Interplay mechanisms and clinical translation. Journal of Neuroinflammation, 20, 165. https://doi.org/10.1186/s12974-023-02853-3
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., … & Pericak‑Vance, M. A. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease. Science, 261(5123), 921–923. https://doi.org/10.1126/science.8346443
d’Errico, P., Meyer-Luehmann, M., & Schilling, S. (2020). Mechanisms of pathogenic tau and Aβ protein spreading. Frontiers in Aging Neuroscience, 12, 265. https://doi.org/10.3389/fnagi.2020.00265
Goate, A., Chartier‑Harlin, M. C., Mullan, M., Brown, J., Crawford, F., Fidani, L., … & Hardy, J. (1991). Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature, 349(6311), 704–706. https://doi.org/10.1038/349704a0
Gulisano, W., Melone, M., Bernardo, A., & Ciotti, M. T. (2018). Role of amyloid-β and tau proteins in Alzheimer’s disease. Frontiers in Aging Neuroscience, 10, 195. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371153/
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P. S., Vendruscolo, M., Iwatsubo, T., Masters, C. L., & Vergallo, A. (2021). The amyloid-β pathway in Alzheimer’s disease. Molecular Psychiatry, 26, 5481–5503. https://doi.org/10.1038/s41380-021-01249-0
Hansson, O., Seibyl, J., Stomrud, E., Zetterberg, H., Trojanowski, J. Q., Bittner, T., … & Blennow, K. (2018). CSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimer’s & Dementia, 14(11), 1470–1481. https://doi.org/10.1016/j.jalz.2018.06.001
.Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer’s disease: Progress and problems on the road to therapeutics. Science, 297(5580), 353–356. https://doi.org/10.1126/science.1072994
Iadecola, C. (2013). The pathobiology of vascular dementia. Neuron, 80(4), 844–866. https://doi.org/10.1016/j.neuron.2013.10.008
Jack, C. R., Jr., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., Liu, E., Molinuevo, J. L., Montine, T., Phelps, C., Rankin, K., Rowe, C. C., Scheltens, P., Siemers, E., Snyder, H. M., … Silverberg, N. (2018). NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 14(4), 535–562. https://doi.org/10.1016/j.jalz.2018.02.018
Kivipelto, M., Mangialasche, F., Ngandu, T., & Solomon, A. (2018). Lifestyle interventions to combat cognitive decline and Alzheimer’s disease. Lancet Neurology, 17(5), 398–412. https://doi.org/10.1016/S1474-4422(18)30037-1
Lane, C. A., Hardy, J., & Schott, J. M. (2018). Alzheimer’s disease. European Journal of Neurology, 25(1), 59–70. https://doi.org/10.1111/ene.13439
Murphy, M. P., & LeVine, H. (2010). Alzheimer’s disease and the amyloid-beta peptide. Journal of Alzheimer’s Disease, 19(1), 311–323. https://doi.org/10.3233/JAD-2010-1221
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., … & Vassar, R. (2006). Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: Potential factors in amyloid plaque formation. Journal of Neuroscience, 26(40), 10129–10140. https://doi.org/10.1523/JNEUROSCI.1202-06.2006
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., & Blennow, K. (2019). Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA, 322(6), 537–547. https://doi.org/10.1001/jama.2019.12125
Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Molecular Medicine, 8(6), 595–608. https://doi.org/10.15252/emmm.201606210
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., … & Sandrock, A. (2016). The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature, 537(7618), 50–56. https://doi.org/10.1038/nature19323
Ou, C.-M., Xue, W.-W., Liu, D., Ma, L., Xie, H.-T., & Ning, K. (2024). Stem cell therapy in Alzheimer's disease: Current status and perspectives. Frontiers in Neuroscience, 18, 1440334. https://doi.org/10.3389/fnins.2024.1440334
van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., Kanekiyo, T., Li, D., Li, Y., Mattson, R., Ransohoff, R. M., Selkoe, D. J., & Sperling, R. (2023). Lecanemab in early Alzheimer’s disease. The New England Journal of Medicine, 388(1), 9–21. https://doi.org/10.1056/NEJMoa2212948
Villemagne, V. L., Fodero-Tavoletti, M. T., Masters, C. L., & Rowe, C. C. (2013). Tau imaging: Early progress and future directions. Lancet Neurology, 12(1), 24–34. https://doi.org/10.1016/S1474-4422(12)70257-2
Yokoyama, M., Kobayashi, H., Tatsumi, L., & Tomita, T. (2022). Mouse models of Alzheimer’s disease. Frontiers in Molecular Neuroscience, 15, 912995. https://doi.org/10.3389/fnmol.2022.912995
National Institute on Aging. (2024). What happens to the brain in Alzheimer’s disease? U.S. Department of Health & Human Services. https://www.nia.nih.gov/health/what-happens-brain-alzheimers-disease
Chen, Y., Li, Q., Liu, W., & Wang, Y. (2023). Tau and neuroinflammation in Alzheimer’s disease. Journal of Neuroinflammation, 20, 133. https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-023-02853-3
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P. S., Vendruscolo, M., Iwatsubo, T., Masters, C. L., & Vergallo, A. (2021). The amyloid-β pathway in Alzheimer’s disease. Molecular Psychiatry, 26, 5481–5503. https://doi.org/10.1038/s41380-021-01249-0
Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Molecular Medicine, 8(6), 595–608. https://doi.org/10.15252/emmm.201606210
Downloads
Posted
Categories
License
Copyright (c) 2026 Research Archive of Rising Scholars
This work is licensed under a Creative Commons Attribution 4.0 International License.
